Drugs / WJMSC-exosome
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06482541 | Jul 2024 → Jul 2025 overdue | androgenetic alopecia | Levit Dermatology | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WJMSC-exosome | “Participants will receive 5 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of...” NCT06482541 ↗ |
| Known as | Wharton's Jelly Mesenchymal Stem Cell-derived Exosome | “The investigators will conduct a double-blind placebo-controlled study to test whether Wharton's Jelly Mesenchymal Stem Cell-derived Exosome (WJMSC-exosome) application with...” NCT06482541 ↗ |
| Modality | Other / unclassified | “Wharton's Jelly mesenchymal stem cell-derived exosome microneedling on the scalp” NCT06482541 ↗ |
| Route | Topical | “Participants will receive 5 billion WJMSC-exosome topical application” NCT06482541 ↗ |